Komori
Governance4893Noile-Immune Biotech Inc.Pharmaceuticals

Corporate Governance Report 2026/04/14

The report includes a schematic diagram showing the internal procedures for making timely disclosures and the allocation of roles among the parties involved. No changes to the governance structure, committees or policy-held shares can be confirmed from the main text.

Worth reading
—
Scored from 0 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Avoiding a definitive answer
How definitive the wording is.

Contents of this filing

This filing does not state the corporate governance structure or the composition of the board of directors.

Contents of this filing
ItemDetails
Items this document does not state (8)
Corporate Governance StructureNumber of directorsNumber of independent officersCommitteePolicy on cross-shareholdingsTakeover defensesControlling shareholderChanges this time

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The apparent purpose is to provide an overview of the timely disclosure system, but no explicit reason is stated in the document.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Corporate Governance Report 2026/04/14 | Noile-Immune Biotech Inc. (4893) timely disclosure | Komori